Navigation Links
Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Date:2/7/2008

but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal(TM) for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase 2 clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cauti
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Last year, Formedix celebrated its partnership with ... data management solutions for clinical trials. The company launched ... data capture (EDC) and clinical data management. Formedix, a ... added TrialMaster to its Transform for EDC product line. ... TrialMaster, is being released this week, in response to ...
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... 2014 - Valentis ... Trendlines Agtech , announced it has signed an ... leading agricultural thermoplastics applications companies. ... combines nanocrystalline cellulose (NCC), a biodegradable, transparent material ... to produce highly improved polymeric films. Used as ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
Breaking Biology Technology:Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... Repligen Corporation (Nasdaq: RGEN ) announced today that it will ... Wednesday, June 9th, 2010 , before the market opens.  The Company President ... conference call and webcast on the same day at 10:00 a.m. EDT ... Company. , , , ...
... June 2 /PRNewswire-Asia-FirstCall/ -- Huiheng Medical,Inc. ("Huiheng" or the ... an agreement to acquire all of the existing and,outstanding shares of ... consisting of the rights to develop,manufacture and market the ClearPath (TM) ... , , ...
... 2 DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... announced its attendance at the Drug Information Association,s 46th Annual Meeting, ... Washington DC June 13-17 . , ... DATATRAK will be exhibiting at Booth #2435 during ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 2Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 3Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 4Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System 5DATATRAK Exhibiting at the DIA's 46th Annual Meeting 2DATATRAK Exhibiting at the DIA's 46th Annual Meeting 3
(Date:7/23/2014)... world by 2050, according to one of the scenarios ... may be advantageous to the physiology and the biochemical ... plants such as Stylosanthes capitata Vogel , a ... as Brazil., The conclusion is from a study carried ... the Ribeiro Preto Faculty of Philosophy, Sciences and Languages ...
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... such as tapeworms, hookworms and a protist called Blastocystis ... new paper that argues we should rethink our views of ... the point, paper co-author Julius Luke even ingested three developmental ... latum . After more than a year with the tapeworms, ... metres each by now, he says he feels fine. , ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3
... release is available in Spanish . , ... at fending off the aging process, known as senescence. To ... plant physiologist Cai-Zhong Jiang is investigating the gene-controlled mechanisms of ... modify flowers, aging-linked genes, or the proteins that are products ...
... Motor Neurone Disease Association is funding its first ever ... of this fatal, neurological condition. Pulling together ... and Prof Sir Ian Wilmut from the University of ... Prof Tom Maniatis of Columbia University New York; the ...
... North American small-mammal communities is so out of whack from ... that the current climate change could push them past a ... say Stanford biologists. The evidence lies in fossils spanning the ... in Northern California. What they found is that although ...
Cached Biology News:What genes help blossoms last longer? 2Harnessing the power of stem cells to unlock the secrets of motor neuron disease 2Harnessing the power of stem cells to unlock the secrets of motor neuron disease 3Harnessing the power of stem cells to unlock the secrets of motor neuron disease 4Small mammals -- and rest of food chain -- at greater risk from global warming than thought 2Small mammals -- and rest of food chain -- at greater risk from global warming than thought 3
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
Biology Products: